Abeona Therapeutics(US:ABEO)2026-03-17 11:30Financial Performance - Abeona reported total revenue of $5.8 million for the year ended December 31, 2025, consisting of $3.4 million in license and other revenues and $2.4 million in net product revenue [3]. - Net income for the year ended December 31, 2025, was $71.2 million, or $1.34 per basic share, compared to a net loss of $(63.7) million in 2024 [8]. - Cash, cash equivalents, and short-term investments totaled $191.4 million as of December 31, 2025 [9]. - Total assets increased to $219.6 million as of December 31, 2025, compared to $108.9 million in 2024 [18]. Research and Development - Research and development (R&D) spending decreased to $26.8 million in 2025 from $34.4 million in 2024, primarily due to the FDA approval of ZEVASKYN [6]. Commercialization and Market Access - The first commercial patient treatment of ZEVASKYN was completed in December 2025, with launch momentum expected to build in the first quarter of 2026 [2]. - Selling, general and administrative (SG&A) expenses increased to $65.0 million in 2025, up $35.1 million from 2024, reflecting the commercial transition following ZEVASKYN's approval [7]. - Abeona expanded patient access to ZEVASKYN by activating The University of Texas Medical Branch as the fourth Qualified Treatment Center [2]. - The company expects average net revenues to normalize as the payer mix expands to include commercially insured patients [4]. - The company anticipates that growing treatment experience will catalyze further demand for ZEVASKYN within the RDEB community [2].